AAP
BHVN

Ardsley Advisory Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Ardsley Advisory Partners’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,500
Closed -$129K – 184
2020
Q4 		$129K Buy
+1,500
New +$127K 0.02% 121

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ardsley Advisory Partners's BHVN Position: Q3 2021 in Review

Ardsley Advisory Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2021, closing a stake of 100,150 shares — an estimated $9.72M sold.

Ardsley Advisory Partners first reported a position in BHVN in Q2 2018 and held it in 11 quarters. The position peaked at $28M in Q4 2019. 249 funds tracked by Wall St. Rank hold BHVN as of Q3 2021.

  • Ardsley Advisory Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2021 after selling out during the quarter.
  • Ardsley Advisory Partners sold 100,150 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2021, an estimated $9.72M.
  • Ardsley Advisory Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018 and held it in 11 quarters.
  • Ardsley Advisory Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $28M in Q4 2019.
  • 249 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2021.

Based on Ardsley Advisory Partners's 13F filing for Q3 2021, filed 15 Nov 2021.